1. Ogden C, Carroll M, Curtin L, McDowell MA, Jahak CJ, Flegal KM. 2006. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295;1549-55.

  1. http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed 01/20/08.

  1. Bray G. Medical consequences of obesity. 2004. J Clin Endocrinol Metab 89;2583-89.

  1. Stein C, Colditz G. 2004. The epidemic of obesity. J Clin Endo Metab 89;2522-25.

  1. Schmidt M, Duncan B. 2003. Diabesity: An inflammatory metabolic condition. Clin Chem Lab Med 41;1120-30.

  1. Silha J, Dresk M, Skrha J, Sucharda P, Nyomba B, Murphy l. 2003. Plasma resistin, adiponectin and leptin levels in leans and obese subjects: corrections with insulin resistance. Eur J Endocrinol 149;331-35.

  1. Trayhurn P, Wood S. 2004. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92;347-55.

  1. Despres JP, Lemieux I, Prud’homme D. 2001. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 322;716-20.

  1. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. 2002. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346(6);393-403.

  1. Foster, G. 2006. The behavioral approach to treating obesity. Am Heart J 151;625-27.

  1. Korner J, Aronne LJ. 2003. The emerging science of body weight regulation and its impact on obesity treatment. J. Clin. Invest 11;565-70.

  1. Lowe M. 2003. Self-regulation of energy intake in the prevention and treatment of obesity: is it feasible? Obes Res 11;44S-59S.

  1. National Institutes of Health, National Heart, Lung, and Blood Institute. 2002. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. NIH publication number 02-4084.

  1. Li Z, Maglione M, Tu W, Majica W, Artebaurn D, Shugarman L, Hilton L, Suttorp M, Solomon V, Shekelle P, Morton S. 2005. Meta- analysis: Pharmacologic treatment of obesity. Ann Intern Med 142; 532-46.

  1. Snow V, Barry P, Fitterman N, Qaseem A, Weiss K. 2005. Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Ann Intern Med 142(7);525-31

  1. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, Mendels J, Ryan DH, Schwartz SL, Scheinbaum ML, Seaton TB. 1999. Sibutramine produces dose-related weight loss. Obes Res 7(2);189-98.

  1. Ryan DH. 2003. Use of sibutramine to treat obesity. Prim Care Clin Office Pract 30;405-26.

  1. Wirth A, Krause J. 2001. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA. 286(11);1331-9.

  1. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. 1999. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 106(2);79-84.

  1. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, Saris WH, Van Gaal LF. 2000. Effect of sibutramine on weight maintenance after weight loss: a randomized trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 356(9248);2119-25.

  1. Wadden T, Berkowitz R, Womble L, Sarwer D, Phelan S, Cato R, Hessen L, Osei S, Kaplan R, Stunkard A. 2005. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 353; 2111-20.

  1. Early JL, Apovian CM, Aronne LJ, Fernstrom MH, Frank A, Greenway FL, Heber D, Kushner RF, Cwik KM, Walch JK, Hewkin AC, Blakesley V. 2007. Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients. Obesity (Silver Spring) 15(6);1464-72.

  1. McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K. 2002. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 16(1);5-11.

  1. Sramek JJ, Leibowitz MT, Weinstein SP, Rowe ED, Mendel CM, Levy B, McMahon FG, Mullican WS, Toth PD, Cutler NR. 2002. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. J Hum Hypertens 16(1);13-9.

  1. McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, Johnson F, Mooradian AD. 2000. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 160(14);2185-91.

  1. Scholze J, Grimm E, Herrmann D, Unger T, Kintscher U. 2007. Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. Circulation 115(15);991-8.

  1. Zannad F, Gille B, Grentzinger A, Bruntz JF, Hammadi M, Boivin JM, Hanotin C, Igau B, Drouin P. 2002. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. AM HEART J 193(3);508-15.

  1. Zhi J, Melia AT, Guerciolini R, Chung J, Kinberg J, Hauptman JB, Patel IH. 1994. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 56(1);82-5.

  1. Carriere F, Renou C, Ransac S, Lopez V, De Caro J, Ferrato F, De Caro A, Fleury A, Sanwald-Ducray P, Lengsfeld H, Beglinger C, Hadvary P, Verger R, Laugier R. 2001. Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers. Am J Physiol Gastrointest Liver Physiol. 281(1);G16-28

  1. Williams G. 2007. Orlistat over the counter. BMJ 335(7631);1163-4.

  1. http://www.myalli.com. Accessed 1/21/08.

  1. Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. 2000. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 8(1);49-61.

  1. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M. 1998. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 352(9123);167-72.

  1. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB. 1999. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 281(3);235-42.

  1. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27(1);155-61.

  1. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J. 1998. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 21(8);1288-94.

  1. Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, Hollander P. 2002. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care 25(6);1033-41.

  1. Lindgarde F. 2000. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 248(3);245-54.

  1. Cavaliere H, Floriano I, Medeiros-Neto G. 2001. Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid). Int J Obes Relat Metab Disord 25(7);1095-9.

  1. Munro JF, MacCuish AC, Wilson EM, Duncan LJP. 1968. Comparison of continuous and intermittent Anorectic Therapy in Obesity. BMJ 10;352-54.

  1. Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM. 2002. Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes Res10(7);633-41.

  1. Jain AK, Kaplan RA, Gadde KM, Wadden TA, Allison DB, Brewer ER, Leadbetter RA, Richard N, Haight B, Jamerson BD, Buaron KS, Metz A. 2002. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res 10(10);1049-56.

  1. Gokcel A, Gumurdulu Y, Karakose H, Melek Ertorer E, Tanaci N, BascilTutuncu N, Guvener N. 2002. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 4(1);49-55.

  1. DeFranzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. 2005. The effects of extenatide (extend-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28;1092-1100.

  1. Hollander P, Maggs DG, Ruggles JA,, Fineman M, Shen L, Kolterman OG, Weyer C. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res 12(4);661-68.

  1. Appolinario JC, Fontenelle LF, Papelbaum M, Bueno JR, Coutinho W. 2002. Topiramate use in obese patients with binge eating disorder: an open study. Can J Psychiatry 47(3);271-3.

  1. Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M; OBES-002 Study Group. 2004. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 28(11);1399-410.

  1. Van Gaal LF, Rissanen LM, Scheen AJ, Ziegler O, Rossner S and for the RIO-Europe Study Group, 2005. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study, Lancet 365;1389–97.

  1. Despres JP, Golay A, Sjostrom L and for the Rimonabant in Obesity-Lipids Study Group, 2005. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353;;2121–34.

  1. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J and for the RIO-North America Study Group. 2006. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. JAMA 295;761–75.

  1. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF and RIO-Diabetes Study Group. 2006. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes. Lancet 368;1160–72.

  1. Curioni C, Andre C. 2006. Rimonabant for overweight or obesity. Available at www.thecochranelibrary.com. Accessed 1/21/08.

  1. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. 2006. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27(1);73-100.

  1. Pi-Sunyer FX, Aronne, LJ, Bray G. 2007. Weight gain induced by psychotropic drugs. Obesity Management 3(4):165-9.

  1. Leslie WS, Hankey CR, Mean MEJ. 2007. Weight gain as an adverse effect of some commonly prescribed drugs: A systematic review. Q J Med 100;395-404.